MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
University of Turin
Turín, ItaliaPublicaciones en colaboración con investigadores/as de University of Turin (2)
2021
-
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105
2018
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204